RxDoctor Payments Data

Laura Buckley, MD

Pulmonary Disease · Plainsboro, NJNPI 1770745416

Payments from drug & device makers

$339in general payments, 2019–2025

Across 24 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$118
  • AstraZeneca$52
  • Insmed, Inc.$31
  • Boehringer Ingelheim$31
  • Pharming Healthcare, Inc.$26
  • Coloplast$19
  • plus $62 from 4 others

What the payments were for

  • Food & beverage$28484%
  • Education$5516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$339 in reported general payments places this provider in the 20th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$178,966
Medicare patients
765
Services billed
2,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate87$1,200,166
Trelegy ElliptaFluticasone/Umeclidin/Vilanter245$254,638
Breo ElliptaFluticasone/Vilanterol387$232,953
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr165$106,743
Spiriva RespimatTiotropium Bromide49$57,931
Dupixent PenDupilumab13$56,541
Fluticasone-SalmeterolFluticasone Propion/Salmeterol128$32,079
Arnuity ElliptaFluticasone Furoate54$21,143
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$20,525
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$18,577
EliquisApixaban19$13,935
Advair DiskusFluticasone Propion/Salmeterol44$13,732
Advair HfaFluticasone Propion/Salmeterol27$13,675
Albuterol Sulfate HfaAlbuterol Sulfate351$13,066
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate53$13,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$31$1,276,674156 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$118$626,015872 claims
AstraZenecaBreztri Aerosphere, Symbicort$52$30,68148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Plainsboro

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →